Charlotte Hubbert

Dr. Charlotte Hubbert is Managing Director and Chief Investment Officer with the Autism Impact Fund where she leads the Life Sciences practice. Charlotte was previously Partner and head of Gates Foundation Venture Capital, a $500mm initiative at the Bill and Melinda Gates Foundation Strategic Investment Fund where she oversaw investing in innovative technologies that supported the foundation’s programs in global health and agriculture. Notably, she led investments and served on the board of directors of Synlogic (Nasdaq: SYBX), Sera Prognostics, Lodo Therapeutics, Agtech Accelerator, Vedanta, and Vir Biotechnology (Nasdaq: VIR). Charlotte currently serves on the BODs of Entrinsic Health and Galileo Biosystems. Prior to joining the foundation, Charlotte was a vice president at H.I.G. BioVentures, investing broadly in healthcare. Charlotte began her career in early-stage biotech, investing at Accelerator Corporation, where she was part of the founding team and oversaw the management of five companies: Oncofactor, Groove Biopharma, Acylin Therapeutics, Xori, and Pharmselex. Charlotte earned a B.S. in microbiology from the University of Washington and a Ph.D. in pharmacology and cancer biology from Duke University for which she received the prestigious Harold Weintraub Award. She did her post-doctoral work in stem cells and regenerative medicine at the Institute for Stem Cells and Regenerative Medicine at the UW. Charlotte is a member of the Kauffman Society of Fellows (Class 14) and serves on the BOD of Life Science Washington, and the steering committees of the Fred Hutch Cancer Institute’s Evergreen Fund, UW Innovation Roundtable, and Columbia University Lab-to-Market initiative. Charlotte has been honored as a Fierce Woman in Biopharma 2016 by FiercePharma, and as a leading Woman in Life Sciences 2016 by Life Science Washington.